Selective MAP4K4 Inhibitors for Cardiomyocyte Death Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical counter-measures fail to effectively target intracellular pathways that lead to cardiac muscle cell death, which is a significant component of heart disease, and there is a lack of direct strategies to enhance cardiomyocyte survival.
Innovation Solution
Development of pharmacological inhibitors targeting Mitogen-Activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4) to suppress cardiac muscle cell death and protect cardiomyocytes from injury during ischemic events, using compounds that selectively modulate MAP4K4 over other kinases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current clinical counter-measures are used to treat heart disease, then general cardiovascular symptoms may be addressed, but they fail to effectively target intracellular pathways that lead to cardiac muscle cell death
Solution Approach 1:
The patent uses MAP4K4 as an intermediary target in the intracellular signaling pathway. By inhibiting MAP4K4, the compound indirectly protects cardiomyocytes from death signals without requiring direct intervention in the complex downstream apoptotic pathways. This mediator approach simplifies the therapeutic strategy while maintaining effectiveness in preventing cardiac muscle cell death.
2Reliability
If broad-spectrum kinase inhibitors are used, then multiple kinases are inhibited, but selectivity towards MAP4K4 is reduced leading to off-target effects
Solution Approach 1:
The patent achieves local quality by designing a compound with specific molecular features that selectively bind to MAP4K4's unique active site architecture. The compound's structure is optimized to recognize specific residues and spatial arrangements in MAP4K4 that differ from other kinases, enabling selective inhibition without affecting other kinase family members. This localized specificity allows the compound to target MAP4K4 precisely while leaving other kinases unaffected.
3Reliability
If direct suppression of cardiomyocyte death pathways is attempted, then cell survival may be enhanced, but clinical trials have failed due to lack of effective target validation
Solution Approach 1:
The patent performs preliminary validation by demonstrating MAP4K4's critical role in cardiomyocyte death pathways using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) before advancing to clinical applications. The preclinical data showing that MAP4K4 inhibition protects against oxidative stress-induced cell death provides a validated target foundation, reducing the risk of clinical trial failure by ensuring target relevance is established in human-relevant models prior to patient testing.
Data Source
Figure 1A
Figure 1B
Figure 1C~1D
AI summary
This invention relates to compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these compounds, for example in a method of treatmentof cardiac conditions.In particular, the present invention relates to compounds of formula (I):